Heart drug vericiguat put to the test in 149 patients after heart attack
NCT ID NCT06321094
First seen Jan 11, 2026 · Last updated May 14, 2026 · Updated 18 times
Summary
This study looked at whether the drug vericiguat helps people who recently had a heart attack (acute coronary syndrome) and have a weak heart pump (ejection fraction below 45%). The main goal was to see if it lowers the chance of dying from heart problems or being hospitalized for heart failure. 149 adults took part, and researchers also checked heart function, a key heart failure marker, and quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
the First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
Conditions
Explore the condition pages connected to this study.